← Back to Screener
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares (CANF)
Price$3.04
Favorite Metrics
Price vs S&P 500 (26W)-92.90%
Price vs S&P 500 (4W)-26.20%
Market Capitalization$20.26M
All Metrics
Book Value / Share (Quarterly)$2.14
P/TBV (Annual)1.99x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-41.59%
Cash Flow / Share (Quarterly)$-3.42
Price vs S&P 500 (YTD)-103.25%
Net Profit Margin (TTM)-2422.41%
EPS (TTM)$-10.30
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-10.30
Revenue Growth (5Y)-12.49%
EPS (Annual)$-5.97
ROI (Annual)-175.75%
Gross Margin (Annual)90.62%
Net Profit Margin (5Y Avg)-1083.32%
Cash / Share (Quarterly)$2.11
Revenue Growth QoQ (YoY)-39.91%
ROA (Last FY)-103.30%
Revenue Growth TTM (YoY)-38.69%
EBITD / Share (TTM)$-10.70
ROE (5Y Avg)-151.64%
Operating Margin (TTM)-2446.13%
Cash Flow / Share (Annual)$-3.42
P/B Ratio1.22x
P/B Ratio (Quarterly)4.73x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)2.14x
Net Interest Coverage (TTM)-165.77x
ROA (TTM)-170.64%
EPS Incl Extra (Annual)$-5.97
Current Ratio (Annual)3.46x
Quick Ratio (Quarterly)3.13x
3-Month Avg Trading Volume0.01M
52-Week Price Return-72.16%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.03
P/S Ratio (Annual)16.85x
Asset Turnover (Annual)0.04x
52-Week High$9000000.00
Operating Margin (5Y Avg)-1099.72%
EPS Excl Extra (Annual)$-5.97
CapEx CAGR (5Y)-40.13%
Tangible BV CAGR (5Y)-2.26%
26-Week Price Return-84.15%
Quick Ratio (Annual)3.15x
13-Week Price Return-27.42%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.46x
Enterprise Value$1.298
Revenue / Share Growth (5Y)59.81%
Asset Turnover (TTM)0.07x
Book Value / Share Growth (5Y)176.98%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-2426.67%
Cash / Share (Annual)$2.11
3-Month Return Std Dev228.74%
Net Income / Employee (TTM)$-3
ROE (Last FY)-175.75%
Net Interest Coverage (Annual)-30.79x
EPS Basic Excl Extra (Annual)$-5.97
Receivables Turnover (TTM)0.23x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-10.30
Receivables Turnover (Annual)71.40x
ROI (TTM)-300.82%
P/S Ratio (TTM)11.25x
Pretax Margin (5Y Avg)-1083.30%
Revenue / Share (Annual)$0.25
Tangible BV / Share (Annual)$0.02
Price vs S&P 500 (52W)-70.54%
Year-to-Date Return-99.99%
5-Day Price Return-0.96%
EPS Normalized (Annual)$-5.97
ROA (5Y Avg)-87.60%
Net Profit Margin (Annual)-2426.67%
Month-to-Date Return-4.11%
EBITD / Share (Annual)$-6.04
Operating Margin (Annual)-2456.79%
ROI (5Y Avg)-151.64%
EPS Basic Excl Extra (TTM)$-10.30
P/TBV (Quarterly)1.05x
P/B Ratio (Annual)4.73x
Pretax Margin (TTM)-2422.41%
Book Value / Share (Annual)$2.14
Price vs S&P 500 (13W)-30.28%
Beta-0.56x
Revenue / Share (TTM)$0.37
ROE (TTM)-300.82%
52-Week Low$450.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CANFCan-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares | 11.25x | -38.69% | — | — | $3.04 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Can-Fite Biopharma is a clinical-stage biopharmaceutical company developing oral small-molecule drugs targeting the A3 adenosine receptor for cancer, inflammatory diseases, and liver disorders. The company's platform exploits selective A3AR expression in diseased cells, potentially enabling safer therapeutic efficacy. Its pipeline includes multiple candidates in Phase II and Phase III clinical development, including Namodenoson, Piclidenoson, and CF602.